Primary overall survival (OS) from OPTiM, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.
Howard L Kaufman
Consultant or Advisory Role - Amgen
Robert Hans Ingemar Andtbacka
Consultant or Advisory Role - Amgen
Research Funding - Amgen
Frances A. Collichio
Consultant or Advisory Role - Amgen
Research Funding - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Morphotek; Novartis
Thomas Amatruda
No relevant relationships to disclose
Neil N. Senzer
No relevant relationships to disclose
Jason Chesney
No relevant relationships to disclose
Keith A. Delman
Research Funding - Amgen
Lynn E. Spitler
Consultant or Advisory Role - Amgen
Igor Puzanov
Consultant or Advisory Role - Amgen
Yining Ye
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Ai Li
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Jennifer L. Gansert
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Robert Coffin
Consultant or Advisory Role - Amgen
Stock Ownership - BioVex
Merrick I. Ross
Consultant or Advisory Role - Amgen
Honoraria - Paradigm Medical Communications
Research Funding - Amgen